AZD4117

PreclinicalBiologic

AstraZeneca

AZD4117 is one of 2 biologic programs targeting Influenza A. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Influenza aActive, not recruiting

Influenza aPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Influenza a

#DrugCompanyPhaseTrials

Baloxavir

IInsight Therapeutics, LLC

Phase 3

1 2

AZD4117

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Influenza a

NCT07128615

Clinical

Trials by Indication[1]

Influenza A1 trial

A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07128615·405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD4117. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD4117 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD4117. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

AZD4117

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Influenza A1 trial

References

Drug Info

Quick Facts

Related News